Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.

Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.

Tadalafil and Finasteride may help treat aggressive melanoma.

Intravaginal testosterone cream improves sexual satisfaction and reduces vaginal discomfort in postmenopausal women on breast cancer treatment without affecting hormone levels.

Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.

Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.

Tofacitinib helps hair regrow in some kids with severe alopecia areata, but more research is needed on long-term effects.

Tofacitinib effectively promotes hair regrowth in children with alopecia areata, but more research on long-term safety is needed.

MK-5108 is safe and shows potential against tumors, especially alone.

Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.

BLZ-100 is safe for use in skin cancer surgery and may help identify cancerous tissue.

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.

Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.

Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.

Targeted therapies for advanced skin cancer often cause hair and nail problems, which need managing to avoid changing the treatment dose.

Baricitinib is generally safe for long-term use in treating severe alopecia areata.

Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.

Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.

Tofacitinib effectively regrew scalp hair in an 11-year-old girl with alopecia areata.

JAK inhibitors can be safely used for alopecia areata in patients with latent hepatitis B or stable tuberculosis with proper monitoring.

A patient with complete hair loss regrew all her hair using tofacitinib.

Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.

Tofacitinib partially improved hair regrowth in a patient with severe hair loss.

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.

Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.

Triptolide effectively and safely reduces actinic keratosis lesions in mice.